hasPharmacogenomicAssociation
P92924
predicate
Indicates that there is a documented relationship between a genetic variant and a drug’s response, efficacy, or toxicity.
Observed surface forms (2)
- associatedWithBiomarker ×3
- polymorphismsAffect ×2
Sample triples (9)
| Subject | Object |
|---|---|
| CYP2C9 | enzyme activity via predicate surface "polymorphismsAffect" ⓘ |
| CYP2C9 | warfarin dose requirements via predicate surface "polymorphismsAffect" ⓘ |
| HGNC:28350 | C9orf72 repeat expansion testing via predicate surface "associatedWithBiomarker" ⓘ |
| Lynparza | BRCA1 mutation via predicate surface "associatedWithBiomarker" ⓘ |
| Lynparza | BRCA2 mutation via predicate surface "associatedWithBiomarker" ⓘ |
| carbamazepine | HLA-A*3101 allele NERFINISHED ⓘ |
| carbamazepine | HLA-B*1502 allele NERFINISHED ⓘ |
| warfarin | CYP2C9 polymorphisms ⓘ |
| warfarin | VKORC1 polymorphisms ⓘ |